How can overlapping of Novolog (insulin aspart protamine/insulin aspart) 70/30 and Lantus (insulin glargine) be prevented?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Preventing Overlapping of Novolog 70/30 and Lantus

To prevent overlapping of Novolog 70/30 and Lantus, administer Lantus in the morning and Novolog 70/30 at breakfast and dinner, maintaining a consistent schedule and monitoring blood glucose levels closely. 1, 2

Understanding the Insulin Types

  • Novolog 70/30 is a premixed insulin containing 70% insulin aspart protamine (intermediate-acting) and 30% insulin aspart (rapid-acting), providing both basal and prandial coverage 3
  • Lantus (insulin glargine) is a long-acting basal insulin with a relatively constant release profile over 24 hours with no pronounced peak 4
  • Using both insulins simultaneously creates risk of insulin stacking and hypoglycemia due to overlapping basal insulin components 1

Recommended Administration Schedule

  • Change the timing of Lantus from bedtime to morning to minimize overlap with the intermediate-acting component of Novolog 70/30 3, 5
  • Administer Novolog 70/30 before breakfast and dinner (typically 2/3 of daily dose before breakfast and 1/3 before dinner) 3, 1
  • Maintain consistent timing between doses - ideally administer Lantus at least 12 hours apart from Novolog 70/30 evening dose 1, 2

Dose Adjustment Strategies

  • When transitioning between insulin regimens, maintain the same total daily dose initially but adjust the distribution 1, 2
  • For patients on Novolog 70/30 twice daily, use 70% of the total daily dose as Lantus in the morning 3, 1
  • Titrate Lantus dose based on fasting glucose values over 1 week 3
  • If fasting glucose values are consistently above target, increase Lantus by 2 units 3
  • If experiencing hypoglycemia (glucose <80 mg/dL), decrease Lantus dose by 2 units 3

Monitoring Recommendations

  • Check blood glucose more frequently during the transition period, focusing on both fasting and postprandial levels 3, 1
  • Target fasting glucose values between 90-150 mg/dL 3
  • Monitor for nocturnal hypoglycemia, which is less common with morning Lantus administration compared to evening dosing 5
  • Use a simplified sliding scale temporarily during transition if needed 3

Common Pitfalls to Avoid

  • Never administer Lantus at the same time as Novolog 70/30 1, 6
  • Avoid using rapid-acting insulin at bedtime to prevent nocturnal hypoglycemia 3
  • Don't convert insulin doses on a 1:1 basis without adjusting distribution between morning and evening doses 1, 2
  • Never mix Lantus with any other insulin in the same syringe 6
  • Don't neglect the importance of consistent meal timing, which is particularly critical with premixed insulin regimens 1, 6

Special Considerations

  • For elderly patients or those at higher risk of hypoglycemia, consider using lower starting doses when transitioning 3, 6
  • If wide glucose excursions are observed, consider simplifying the insulin regimen further 3
  • For patients with cognitive or functional decline, a simpler regimen with fewer daily injections may be preferred 3

References

Guideline

Insulin Regimen Conversion

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Switching from NPH Insulin to 70/30 Insulin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Insulin glargine (Lantus).

International journal of clinical practice, 2002

Guideline

Humalog 75/25 Usage and Dosing Guidelines for Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.